Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 2 1

Status

Recruiting 1Completed 1Active not recruiting 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 3Breast 3Head & Neck 2Gynecologic 2Genitourinary 2Thoracic 1

Conditions

Colorectal Neoplasms 80Stomach Neoplasms 66Rectal Neoplasms 39Pancreatic Neoplasms 31Colonic Neoplasms 27Esophageal Neoplasms 24Lymphoma, Large B-Cell, Diffuse 20Neoplasms 19Adenocarcinoma 19Cholangiocarcinoma 16Neoplasm Metastasis 15Adenocarcinoma Of Esophagus 14Biliary Tract Neoplasms 12Carcinoma, Non-Small-Cell Lung 11Parkinson Disease 4, Autosomal Dominant Lewy Body 10Ovarian Neoplasms 10Gastrointestinal Neoplasms 7Gallbladder Neoplasms 7Carcinoma, Hepatocellular 7Locally Advanced Rectal Cancer 6Esophageal Squamous Cell Carcinoma 6Endometrial Neoplasms 6Recurrence 4Lymphoma 4Carcinoma 4Bile Duct Neoplasms 4Advanced Solid Tumors 4Triple Negative Breast Neoplasms 3Squamous Cell Carcinoma of Head and Neck 3Peritoneal Neoplasms 3

Interventions

pembrolizumab 96Carboplatin 67Paclitaxel 56Cyclophosphamide 40Capecitabine 30Specimen Handling 28sacituzumab govitecan 26130-nm albumin-bound paclitaxel 25Gemcitabine 22Magnetic Resonance Spectroscopy 21olaparib 20Doxorubicin 20Albumin-Bound Paclitaxel 20Taxes 19Biopsy 19Drug Therapy 16atezolizumab 14Nivolumab 14toripalimab 12Radiotherapy 12Epirubicin 12durvalumab 11Docetaxel 10Cisplatin 10Bevacizumab 10eribulin 9fludarabine 8Standard of Care 7Radiation 7Injections 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Triple Negative Breast Neoplasms × Oxaliplatin × 1 year × Clear all
NCT07318805 2026-05-08

A Study to Learn About the Study Medicine Called PF-08032562 in People With Advanced or Metastatic Solid Tumors

Pfizer

Phase 1 Recruiting
260 enrolled
BreastGastrointestinal

Breast Neoplasms, Colonic Neoplasms, Colorectal Neoplasms, Triple Negative Breast Neoplasms

NCT05891171 2026-03-31

ARC-25

Arcus Biosciences, Inc.

Phase 1 Active not recruiting
40 enrolled
BreastGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Esophageal Neoplasms, Ovarian Neoplasms, Stomach Neoplasms, Triple Negative Breast Neoplasms

NCT05007106 2025-08-14

KEYVIBE-005

Merck Sharp & Dohme LLC

Phase 2 Completed
613 enrolled
BreastGastrointestinalGenitourinaryGynecologicHead & Neck

Parkinson Disease 4, Autosomal Dominant Lewy Body, Squamous Cell Carcinoma of Head and Neck, Urinary Bladder Neoplasms, Uterine Cervical Neoplasms, Esophageal Neoplasms, Gallbladder Neoplasms, Carcinoma, Hepatocellular, Ovarian Neoplasms, Stomach Neoplasms, Endometrial Neoplasms, Cholangiocarcinoma, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡